U.S. officials are warning about a potentially life-threatening issue with smartphone apps that help manage diabetes.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

A study led by researchers from Peking University and published in Health Data Science reveals a sharp rise in the burden of ...

We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to ...

Debbie Allen has never let bias stop her, whether in Hollywood or healthcare. Now, she’s using her voice to fight diabetes ...

It’s important to create health-related goals that are easy to maintain. Here are some simple switches you can make today ...

New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

Even a mild infection with COVID-19 can promote clogged arteries, increasing the risk of heart attack in some people, a new ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

There is an eternal chicken-or-egg debate over obesity and Type 2 diabetes—science still can’t quite pin down which causes ...

Recent research reported that women with endometriosis have an approximately 20% increased risk for stroke and a 35% greater risk for heart attack compared with women without endometriosis. Although ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...